CDXSCodexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Codexis (CDXS) Q2 2026 Earnings Call Transcript Product revenue surged 78% YoY as launches drive margin expansion and extend cash runway. | ||
 Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | ||
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... Codexis Inc (CDXS) reports improved gross margins and advances ECO Synthesis platform despite slight revenue dip, with cash runway extended through 2028. | ||
 Codexis, Inc. Q2 2026 Earnings Call Summary Moby summary of Codexis, Inc.'s Q2 2026 earnings call | ||
 Codexis Q2 Earnings Call Highlights Codexis (NASDAQ:CDXS) reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing. Net | ||
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||